Eye90 microspheres® for treating unresectable liver cancer

Current imaging options to assess the responses of liver cancer patients to treatment suffer from blurry resolution, making it hard to develop radiotherapy plans.

Eye90 Microspheres, developed by ABK Biomedical, enables superior CT-based dosimetry , allowing for more more accurate dose estimates for treatment planning.

This work was awarded the Best Paper of the Year in the journal EJNMMI, and is being further assess in the Route90  Study.

Read the original research:  https://doi.org/10.1186/s40658-022-00447-1